Síndrome de ovario poliquístico en mujeres con diabetes mellitus tipo 1

Gilda Monteagudo Peña, José Arturo Hernández Yero, Rosana R. Cobas Guzmán, Manuel Vera González, Juan Carlos Vázquez Niebla

Texto completo:

PDF

Resumen

Introducción: La resistencia a la insulina e hiperinsulinismo se consideran el nexo que subyace en la relación del síndrome de ovario poliquístico con la diabetes mellitus tipo 2. Sobre esa base se postula que el síndrome pudiera ser también más frecuente en la diabetes tipo 1, pues la administración exógena de insulina podría ser suprafisiológica.

Objetivo: Revisar la evidencia sobre el tema e identificar la frecuencia y características del síndrome de ovario poliquístico en mujeres con diabetes mellitus tipo 1.

Métodos: Se realizó una revisión bibliográfica tipo estado del arte y se estudiaron 45 mujeres con diabetes mellitus tipo 1. Se identificaron y se compararon aquellas con o sin síndrome de ovario poliquístico según los criterios de Rotterdam.

Conclusiones: Los estudios sugieren mayor frecuencia del síndrome de ovario poliquístico en mujeres con diabetes mellitus tipo 1. Por su alcance reproductivo y cardiometabólico sería recomendable incluir su pesquisa en todas las mujeres con diabetes mellitus tipo 1 para poder hacer recomendaciones basadas en la evidencia. Puesto que los antecedentes personales y familiares parecen estar implicados en la patogenia, la prevención posible debe ser un propósito.

Palabras clave: síndrome de ovario poliquístico; resistencia a la insulina; hiperinsulinismo; diabetes mellitus tipo 1.

Referencias

Achard C, Thiers J. Le virilisme pilaire et son association a l’insuffisance glycolytique (diabete des femmes a barb). Bull Acad Natl Med. 1921 [acceso: 05/10/2021];86:51-64. Disponible en: https://rarediseases.org/rare-diseases/achard-thiers-syndrome/

Gambineri A, Pelusi C. Sex hormones, obesity and type 2 diabetes: is there a link? Endocr Connect. 2019;8(1):R1-9. DOI: https://doi.org/10.1530/EC-18-0450

Yang R, Yang S, Li R, Liu P, Qiao J, Zhang Y. Effects of hyperandrogenism on metabolic abnormalities in patients with polycystic ovary syndrome: a meta-analysis. RB&E. 2016 [acceso: 05/10/2021];14. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069996/

Lo JC, Yang J, Gunderson EP, Hararah MK, Gonzalez JR, Ferrara A. Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women with Polycystic Ovary Syndrome. Hindawi J Diabetes Research.2017;5250162:5. DOI: https://doi.org/10.1155/2017/5250162

Macut D, Bjekić-Macut J, Rahelić D, Doknić M. Insulin and the polycystic ovary syndrome. Diabetes Res Clin Prat. 2017;130:163-70. DOI: https://doi.org/10.1016/j.diabres.2017.06.011

Nolan CJ, Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. Diab Vasc Dis Res. 2019;16(2):118-27. DOI: https://doi.org/10.1177/1479164119827611

McEwen B, Hartmann G. Insulin resistance and polycystic ovary syndrome (PCOS): Part 1. The impact of insulin resistance. J Austral Tradit Med Soc. 24, No. 4, Summer 2018 [acceso: 05/10/2021];24(4):214-9. Disponible en: https://search.informit.com.au/documentSummary;dn=079531226146584;res=IELHEA>

Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary síndrome. Hum Reprod. 2018;33(9):1602-18. DOI: https://doi.org/10.1093/humrep/dey256

Ollila MM, West S, Keinänen Kiukaanniemi S, Jokelainen J, Auvinen J, Puukka K, et al. Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus-a prospective, population-based cohort study. Hum Reprod. 2017;32(2):423-31. DOI: https://doi.org/10.1093/humrep/dew329

Rubin KH, Glintborg D, Nybo M, Abrahamsen B, Andersen M. Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102(10):3848-57. DOI: https://doi.org/10.1210/jc.2017-01354

Escobar Morreale HF, Roldán B, Barrio R, Alonso M, Sancho J, de la Calle H, et al. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2000;85(11):4182-7. DOI: https://doi.org/10.1210/jc.85.11.4182

Codner E, Escobar Morreale HF. Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2007;92(4):1209-16. DOI: https://doi.org/10.1210/jc.2006-2641

Codner E, Soto N, Lopez P, Trejo L, Ávila A, Eyzaguirre FC, et al. Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. J. Clin Endocrinol Metab. 2006;91(6):2250-6. DOI: https://doi.org/10.1210/jc.2006-0108

Codner E, Iñíguez G, Villarroel C, Lopez P, Soto N, Petermann T, et al. Hormonal profile in women with polycystic ovarian syndrome with or without type 1 diabetes mellitus. J Clin Endocrinol Metab. 2007;92(12):4742-6. DOI: https://doi.org/10.1210/jc.2007-1252

Roldán B, Escobar Morreale HF, Barrio R, de La Calle H, Alonso M, García Robles R, et al. Identification of the source of androgen excess in hyperandrogenic type 1 diabetic patients. Diabetes Care. 2001;24(7):1297-9. DOI: https://doi.org/10.2337/diacare.24.7.1297

Bizzarri C, Benevento D, Ravà L, Patera IP, Schiaffini R, Ciampalini P, et al. Ovarian hyperandrogenism in adolescents and young women with type I diabetes is primarily related to birth weight and body mass index. Fertil Steril. 2011;96(6):1497-1502.e1. DOI: https://doi.org/10.1016/j.fertnstert.2011.09.023

Zachurzok A, Deja G, Gawlik A, Drosdzol Cop A, Małecka Tendera E. Hyperandrogenism in adolescent girls with type 1 diabetes mellitus treated with intensive and continuous subcutaneous insulin therapy. Endokrynol Pol. 2013 [acceso: 05/10/2021];64:121-8. Disponible en: https://journals.viamedica.pl/endokrynologia_polska/article/view/34291/32349

Amato MC, Guarnotta V, Ciresi A, Modica R, Panto F, Giordano C. No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus. J Clin Endocrinol Metab. 2014;99(1):203-11. DOI: https://doi.org/10.1210/jc.2013-2669

Escobar Morreale HF, Roldán Martín MB. Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis. Diabetes Care. 2016;39(4):639-48. DOI: https://doi.org/10.2337/dc15-2577

Glintborg D, Andersen M. Morbidity in polycystic ovary syndrome. Eur J Endocrinol. 2017;176: R53-65. DOI: https://doi.org/10.1530/EJE-16-0373

ESHRE/ASRM - Sponsored consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. DOI: https://doi.org/10.1016/j.fertnstert.2003.10.004

Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27(10):3067-73. DOI: https://doi.org/10.1093/humrep/des232

Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-9. DOI: https://doi.org/10.1210/jc.2003-032046

Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X. Prevalence of polycystic ovary syndrome and related disorders in Mexican women. Gynecol Obstet Invest. 2010;69(4):274-80. DOI: https://doi.org/10.1159/000277640

March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544-51. DOI: https://doi.org/10.1093/humrep/dep399

Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol. 2011;9:39. DOI: https://doi.org/10.1186/1477-7827-9-39

Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova Jordan L, Azziz R. Criteria, prevalence and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(01):6-15. DOI: https://doi.org/10.1016/j.fertnstert.2016.05.003

Asunción M, Calvo RM, San Millán JL, Sancho J, Ávila S, Escobar Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(7):2434-8. DOI: https://doi.org/10.1210/jcem.85.7.6682

Miulescu RD, Musat M, Margina D, Poiana C, Danoiu S. The prevalence of hirsutism and polycystic ovary syndrome in women with type 1 diabetes mellitus. Gineco Ro. 2009 [acceso: 05/10/2021];5:17-182. Disponible en: http://gineco.eu/system/revista/7/178-182.pdf

Samara Boustani D, Colmenares A, Elie C, Dabbas M, Beltrand J, Caron V, et al. High prevalence of hirsutism and menstrual disorders in obese adolescent girls and adolescent girls with type 1 diabetes mellitus despite different hormonal profiles. Eur J Endocrinol. 2012;166(2):307-16. DOI: https://doi.org/10.1530/EJE-11-0670

Miyoshi A, Nagai S, Takeda M, Kondo T, Nomoto H, Kameda H, et al. Ovarian morphology and prevalence of polycystic ovary syndrome in Japanese women with type 1 diabetes mellitus. J Diabetes Investig. 2013;4(3):326-9. DOI: https://doi.org/10.1111/jdi.12040

Łebkowska A, Adamska A, Karczewska Kupczewska M, Nikołajuk A, Otziomek E, Milewski R, et al. Serum anti-Müllerian hormone concentration in women with polycystic ovary syndrome and type 1 diabetes mellitus. Metabolism. 2016;65(5):804-11. DOI: https://doi.org/10.1016/j.metabol.2016.02.005

Busiah K, Colmenares A, Bidet M, Tubiana Rufi N, Levy Marchal C, Delcroix C, et al. High prevalence of polycystic ovary syndrome in type 1 diabetes mellitus adolescents: is there a difference depending on the NIH and Rotterdam criteria? Horm Res Paediatr. 2017;87:333-41. DOI: https://doi.org/10.1159/000471805

Reinauer C, Bollow E, Fröhlich Reiterer E, Laubner K, Bergis D, Schöfl C, et al. Polycystic ovary syndrome (PCOS) in juvenile and adult type 1 diabetes in a german/austrian cohort. Exp Clin Endocrinol Diabetes. 2017;125(10):661-8. DOI: https://doi.org/10.1055/s-0043-104701

Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2022 Gilda Monteagudo Peña, Jose Arturo Hernñandez Yero, Rosana R Cobas Guzmán, Manuel Vera Gonzalez, Juan Carlos Vasquez Niebla

Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.